Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
- Status
- RECRUITING
- Phase
- PHASE2
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Status
- RECRUITING
- Phase
- PHASE3
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE2
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases
- Status
- RECRUITING
- Phase
- PHASE1
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2